Esperion Therapeutics, Inc. (ESPR)

Esperion Therapeutics Revenue

In the year 2023, Esperion Therapeutics had annual revenue of $116.33M with 54.14% growth. Revenue in the quarter ending December 31, 2023 was $32.25M with 71.38% year-over-year growth.

• Revenue (ttm): $116.33M
• Revenue Growth: +54.14%
• P/S Ratio: 2.78
• Revenue / Employee: $484,725
• Employees: 240
• Market Cap: 323.79M USD

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2023	116.33M	40.86M	54.14%
Dec 31, 2022	75.48M	-2.97M	-3.79%
Dec 31, 2021	78.45M	-149.10M	-65.52%
Dec 31, 2020	227.55M	79.18M	53.37%
Dec 31, 2019	148.36M	-	-
Dec 31, 2018	0	-	-
Dec 31, 2017	0	-	-
Dec 31, 2016	0	-	-
Dec 31, 2015	0	-	-
Dec 31, 2014	0	-	-
Dec 31, 2013	0	-	-
Dec 31, 2012	0	-	-
Dec 31, 2011	0	-	-

Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.